In Life Sciences, Sofinnova Partners focuses on ambitious projects developing new therapeutics in both biopharmaceuticals and medical devices.
Priority is given to companies that :
Click here for the site of Sofinnova Ventures, our sister firm in San Francisco http://www.sofinnova.com
Percutaneous aortic valve replacement is a technology breakthrough for patients who will need only a few days of hospitalisation.
Corevalve
Nanobodies®, derived from natural single chain antibodies in Camelides, will be the next generation therapeutic antibodies. The anti-TNFalpha is the first under clinical investigation.
Ablynx
Producing glyconjugates in a single step is the challenge GlycoVaxyn is facing in order to get vaccins cheaper and easier to produce.
GlycoVaxyn
Diallertest® Milk is becoming the standard of diagnostic for young children milk allergy. DBV is developping this VIASKIN® technology to diagnose and treat other allergies like peanuts…
DBV Technologies
Alosteric modulation of m-gluR receptors is on the forefront of innovations for new CNS drugs and specifically for anxiety, depression and schizophrénia.
Addex Pharmaceuticals
